Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2025)

Protalix BioTherapeutics has reported Operating Leases over the past 7 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $6.9 million for Q4 2025, up 72.31% from a year ago — trailing twelve months through Dec 2025 was $6.9 million (up 72.31% YoY), and the annual figure for FY2025 was $6.9 million, up 72.31%.
  • Operating Leases for Q4 2025 was $6.9 million at Protalix BioTherapeutics, up from $6.8 million in the prior quarter.
  • Over the last five years, Operating Leases for PLX hit a ceiling of $6.9 million in Q4 2025 and a floor of $3.8 million in Q1 2025.
  • Median Operating Leases over the past 5 years was $4.3 million (2021), compared with a mean of $4.5 million.
  • Peak annual rise in Operating Leases hit 72.31% in 2025, while the deepest fall reached 15.29% in 2025.
  • Protalix BioTherapeutics' Operating Leases stood at $4.4 million in 2021, then decreased by 4.73% to $4.2 million in 2022, then grew by 10.84% to $4.6 million in 2023, then decreased by 12.88% to $4.0 million in 2024, then soared by 72.31% to $6.9 million in 2025.
  • The last three reported values for Operating Leases were $6.9 million (Q4 2025), $6.8 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.